ProCE Banner Activity

Contemporary Use of PARP Inhibitors in Advanced Ovarian Cancer

Clinical Thought

Review this expert commentary from a clinical pharmacist about important recent advances in the selection of PARP inhibitors as maintenance therapy for patients with advanced ovarian cancer.

Released: July 12, 2023

Share

Faculty

Stephanie Shuey

Stephanie Shuey, PharmD, BCOP

Clinical Pharmacist- Gynecologic Oncology
Department of Pharmacy
Duke University Medical Center
Durham, North Carolina 

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from GSK and Novocure, Inc.

GSK

Novocure, Inc

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Stephanie Shuey, PharmD, BCOP

Clinical Pharmacist- Gynecologic Oncology
Department of Pharmacy
Duke University Medical Center
Durham, North Carolina 

Stephanie Shuey, PharmD, BCOP: consultant/advisor/speaker: GlaxoSmithKline, Immunogen.